AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PHILADELPHIA -- A testosterone patch significantly improved low sexual interest in naturally menopausal women with hypoactive sexual desire disorder, according to study results presented at the annual meeting of the American Society for Reproductive Medicine.
The randomized, double-blind, placebo-controlled phase III study is the largest to date on this subject and included 549 women (mean age 54 years) who were taking estrogen either with or without progesterone.
The research was funded by Procter & Gamble Pharmaceuticals, which makes the patch, and was conducted in 58 centers in the United States, Canada, and Australia. The testosterone patch has not been approved by the Food and Drug Administration for treating women with low sexual desire.
At 24 weeks, women randomized to the patch, which delivered 300 mcg of testosterone transdermally daily, had significantly more sexual desire and activity and significantly less distress, compared with women in the placebo group, reported Robin Kroll, M.D., codirector of the Women's Clinical Research Center in Seattle and the North Seattle Women's Group Menopause Center.
These outcomes were measured using the Profile of Female Sexual Function (PFSF) and the Personal Distress Scale (PDS).
Whereas women taking ...
Source: HighBeam Research, Testosterone patch significantly improved low sexual interest in...